Drug Trial Radar · NCT07001475
A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder
Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
78
Actual
Start
Aug 12, 2025
Primary completion
Aug 6, 2026
Study completion Aug 6, 2026
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Jun 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with certain mental health conditions. The purpose of this study is to find out how a medicine called BI 3031185 is tolerated by people with certain mental health conditions. Participants are put into 2 groups of equal size randomly, which means by chance. Group 1 takes a single dose of BI 3031185 and Group 2 takes placebo. After a 2-week break, Group 1 takes placebo and Group 2 takes a single dose of BI 3031185. Participants take BI 3031185 and placebo as tablets. Participants are in the study for about 3 months. They visit the study site 6 times and have 3 phone or video call visits. For 2 of the visits, participants stay overnight at the study site for 2 nights. During all the visits, doctors check participants' health and take note of any unwanted effects.
Conditions
- Borderline Personality Disorder
- Attention Deficit Hyperactivity Disorder
Interventions
BI 3031185Drug
BI 3031185
PlaceboDrug
Placebo matching BI 3031185
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with borderline personality disorder (BPD) reporting adverse events (AEs) deemed by the investigator to be related to the investigational medicinal product (IMP) from IMP administration to End of Study (EoS)Time frame: Up to 28 days
- Number of participants with attention deficit/hyperactivity disorder (ADHD) reporting AEs deemed by the investigator to be related to the IMP from IMP administration to EoSTime frame: Up to 28 days
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Charité Research Organisation GmbH
Berlin, Germany
Universitätsklinikum Bonn AöR
Bonn, Germany
Universitätsklinikum Frankfurt
Frankfurt am Main, Germany
Martin-Luther-Universität Halle-Wittenberg
Halle, Germany
Rheinhessen-Fachklinik Mainz
Mainz, Germany
Zentralinstitut für seelische Gesundheit
Mannheim, Germany
Universitätsklinikum Tübingen
Tübingen, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.